Ligand Pharmaceuticals Incorporated
LGND
$294.60
$5.782.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 54.89% | 51.24% | 60.40% | 64.83% | 40.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.89% | 51.24% | 60.40% | 64.83% | 40.54% |
| Cost of Revenue | -31.54% | -41.18% | 194.57% | 198.12% | 139.92% |
| Gross Profit | 118.87% | 121.81% | 28.02% | 28.89% | 7.55% |
| SG&A Expenses | 16.14% | 9.23% | 17.54% | 34.74% | 50.38% |
| Depreciation & Amortization | -1.95% | -1.46% | -0.76% | -0.51% | 0.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.66% | -12.55% | 53.28% | 65.41% | 60.86% |
| Operating Income | 800.13% | 708.84% | 105.03% | 60.47% | -279.21% |
| Income Before Tax | 381.63% | 214.76% | 6,212.95% | 7.08% | -259.40% |
| Income Tax Expenses | 571.99% | 209.95% | 426.82% | 6.10% | -179.43% |
| Earnings from Continuing Operations | 359.97% | 215.79% | 3,186.63% | 7.38% | -280.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 359.97% | 215.79% | 3,186.63% | 7.38% | -280.02% |
| EBIT | 800.13% | 708.84% | 105.03% | 60.47% | -279.21% |
| EBITDA | 545.18% | 622.13% | 38.99% | 17.81% | -53.08% |
| EPS Basic | 350.86% | 210.12% | 12,799.80% | -9.12% | -264.26% |
| Normalized Basic EPS | 401.10% | 342.33% | 438.58% | -371.44% | -809.82% |
| EPS Diluted | 333.43% | 203.39% | 3,710.73% | -17.72% | -273.26% |
| Normalized Diluted EPS | 381.81% | 329.31% | 412.51% | -424.68% | -818.03% |
| Average Basic Shares Outstanding | 4.40% | 5.23% | 6.38% | 7.57% | 7.51% |
| Average Diluted Shares Outstanding | 9.12% | 9.33% | 9.98% | 8.96% | 7.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |